Supplements

Red yeast rice: monacolin K and lovastatin, variable products, cholesterol and coronary-event evidence, citrinin, newer safety assessment, and changing claims

7 sources · Latest source check 2026-10-09 UTC

On this page

Red yeast rice is rice fermented with a fungus. Some preparations contain monacolin K, chemically identical to lovastatin. Product composition varies, and biological origin does not remove statin-like risks. The amount of fermented rice on a label does not establish the amount of active ingredient.[1][2]

Four distinctions to retain

Four distinctions to retain
Term	Meaning
Red yeast rice	A fermented preparation; technically the organism is a mold.[1]
Monacolin K	An active constituent structurally identical to lovastatin.[1]
Citrinin	A possible contaminant that can damage kidneys.[1]
Secondary prevention	Preventing further events in people with prior cardiovascular disease.[3]
Legal restriction	A product rule, different from a guaranteed safe exposure.[5]

A 2017 analysis found very different active-ingredient quantities

Cohen and colleagues analyzed 28 brands from mainstream US retailers. Monacolin K was undetectable in two. Among the others, its quantity per fixed amount of red yeast rice varied more than sixtyfold. Manufacturer-recommended daily servings produced a range exceeding 120-fold. This was a sampled-product analysis, rather than testing every current product or future batch.[2]

The fermented-rice mass is not a standardized drug exposure

Two products with the same rice mass can supply different monacolin quantities. A result from a defined extract therefore cannot be transferred using capsule count or grams of fermented material alone. Exact batch assays, labeling and changes since the study require checking. The historical analysis demonstrates why product equivalence cannot simply be assumed.[2]

Relative reduction and product generalization are separate issues

Those frequencies correspond to a 4.7-percentage-point absolute difference and an approximately 45% relative reduction. The result concerns that extract in secondary prevention, rather than every US supplement or healthy person starting primary prevention. Full background-treatment, endpoint-adjudication, missing-data and sponsor-role appraisal remains pending; the trial does not settle the modern benefit–risk balance for an individual.[3]

The 2025 assessment retained the earlier safety concerns

EFSA reviewed additional analytical, clinical, case-report and post-marketing data. It reiterated concern about severe muscle and liver effects reported with monacolin K exposures as low as 3 mg/day. Small trials designed to measure cholesterol changes may be inadequate to detect uncommon harms. A lack of events in such studies cannot establish the absence of important risks.[4]

Monacolin safety and contaminant quality are different assessments

The opinion concerned monacolins in supplements. It did not evaluate a full benefit–risk balance or contaminants and adulterants. Its inability to establish a safe intake therefore should not be recast as a precise individual risk estimate, a recommendation to take a lower amount, or a certificate for a tested commercial product.[4]

The 2022 European restriction was not a safe-intake guarantee

EU Regulation 2022/860 required a daily portion to provide less than 3 mg of monacolins and specified content labeling and warnings. The warnings included pregnancy/lactation, people below eighteen or above seventy, cholesterol-lowering medicines and concurrent red-yeast-rice products. This explains the dated rule; full subsequent legal and national implementation review remains pending.[5]

A regulatory ceiling does not determine a personal regimen

A restriction sets conditions for products; it does not establish that every smaller amount is effective or safe. The unit concerns monacolins, not grams of rice. Regulatory status, a permitted health claim, medicinal approval and clinical effectiveness are separate questions and may differ between jurisdictions.[5]

The former European cholesterol claim was removed in 2024

Regulation 2024/2041 deleted the red-yeast-rice entry from the EU permitted-health-claim list. Its explanation connects the removal to the conflict between the old claim’s exposure conditions and the later monacolin restriction. An older positive claim assessment should not be presented as a currently permitted claim or as evidence of guaranteed safety.[6]

The August 2026 laboratory study examined manufacturing ingredients

Nezi and colleagues characterized 27 commercial semi-processed ingredients intended for supplement manufacturing. Monacolin and other chemical profiles varied. A constituent called dehydromonacolin K correlated with selected toxicity responses in liver cancer cells and primary skeletal-muscle cells. These were ingredient analyses and cell experiments, rather than a randomized human safety or effectiveness trial.[7]

No association under a cell experiment’s conditions does not establish human safety

Monacolin K and its hydroxy-acid form did not significantly correlate with toxicity under the tested conditions. That limited finding cannot negate human case reports, certify all products or quantify a person’s risk. Exploratory protein-pattern differences were hypothesis-generating. Complete assay validity, exposure translation, sponsor roles and replication appraisal remain outstanding.[7]

Statin-like interactions and contamination remain relevant

NCCIH describes statin-like muscle, liver and kidney risks and medicine interactions when products contain substantial monacolin K. Citrinin presents a separate kidney-toxicity concern. Pregnancy and breastfeeding safety studies are lacking. NCCIH also describes US marketing restrictions for products with enhanced or added lovastatin; that agency explanation is not individual product clearance.[1]

Evidence & uncertainty

EFSA’s February 2025 assessment could not establish a monacolin intake without safety concerns, including below 3 mg/day. This is different from a finding that every exposure causes harm. It also differs from an efficacy or benefit–risk appraisal, which was outside that assessment’s mandate.[4]

Selected-source overview · Independent review pending

Published questions

Is red yeast rice monacolin K structurally different from lovastatin?

Selected-source overview · Independent review pending. Read the evidence context.

They are structurally identical.[1]

Evidence behind this answer

Red Yeast Rice: What You Need To Know
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Definition, monacolin identity, contaminants, statin-like harms and stated US marketing policy